Theradaptive, a clinical-stage biotechnology company pioneering targeted protein therapeutics for tissue regeneration, is pleased to announce the appointment of Daniel Wolf as Chief Financial Officer ...

Enlivex Therapeutics (ENLV) announced that the Company completed enrollment of all patients in the Phase II stage of its randomized, ...

Alector has completed subject enrolment in the 76-week, randomised, Phase II PROGRESS-AD trial, which is assessing the efficacy and safety of AL101/GSK4527226, in individuals with early Alzheimer ...

Enlivex Therapeutics Ltd. has announced the completion of patient enrollment in the Phase II stage of its clinical trial for Allocetra™, an immunotherapy for moderate to severe knee ...

Take your time vetting vendors, ask the tough questions, and never settle for support that will vanish after implementation.

Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced its interim report for January-March 2025.

(RTTNews) - BriaCell Therapeutics Corp. (BCTX), Tuesday announced that enrollment is rapidly accelerating in its ongoing pivotal Phase 3 clinical trial evaluating Bria-IMT in combination with an ...